Omeros PE Ratio 2010-2023 | OMER
Current and historical p/e ratio for Omeros (OMER) from 2010 to 2023. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Omeros PE ratio as of May 13, 2024 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Omeros PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2024-05-13 | 3.75 | 0.00 | |
| 2023-12-31 | 3.27 | $-1.88 | 0.00 |
| 2023-09-30 | 2.92 | $0.32 | 9.13 |
| 2023-06-30 | 5.44 | $0.64 | 8.50 |
| 2023-03-31 | 4.65 | $0.74 | 6.28 |
| 2022-12-31 | 2.26 | $0.75 | 3.01 |
| 2022-09-30 | 3.15 | $3.18 | 0.99 |
| 2022-06-30 | 2.75 | $3.10 | 0.89 |
| 2022-03-31 | 6.01 | $3.13 | 1.92 |
| 2021-12-31 | 6.43 | $3.09 | 2.08 |
| 2021-09-30 | 13.79 | $-1.99 | 0.00 |
| 2021-06-30 | 14.84 | $-2.29 | 0.00 |
| 2021-03-31 | 17.80 | $-2.44 | 0.00 |
| 2020-12-31 | 14.29 | $-2.40 | 0.00 |
| 2020-09-30 | 10.11 | $-2.38 | 0.00 |
| 2020-06-30 | 14.72 | $-2.05 | 0.00 |
| 2020-03-31 | 13.37 | $-1.73 | 0.00 |
| 2019-12-31 | 14.09 | $-1.70 | 0.00 |
| 2019-09-30 | 16.33 | $-1.60 | 0.00 |
| 2019-06-30 | 15.69 | $-2.08 | 0.00 |
| 2019-03-31 | 17.37 | $-2.49 | 0.00 |
| 2018-12-31 | 11.14 | $-2.61 | 0.00 |
| 2018-09-30 | 24.41 | $-2.47 | 0.00 |
| 2018-06-30 | 18.14 | $-1.82 | 0.00 |
| 2018-03-31 | 11.17 | $-1.45 | 0.00 |
| 2017-12-31 | 19.43 | $-1.17 | 0.00 |
| 2017-09-30 | 21.62 | $-1.28 | 0.00 |
| 2017-06-30 | 19.91 | $-1.46 | 0.00 |
| 2017-03-31 | 15.12 | $-1.45 | 0.00 |
| 2016-12-31 | 9.92 | $-1.65 | 0.00 |
| 2016-09-30 | 11.16 | $-1.72 | 0.00 |
| 2016-06-30 | 10.52 | $-1.91 | 0.00 |
| 2016-03-31 | 15.34 | $-2.03 | 0.00 |
| 2015-12-31 | 15.73 | $-2.00 | 0.00 |
| 2015-09-30 | 10.96 | $-2.09 | 0.00 |
| 2015-06-30 | 17.99 | $-2.10 | 0.00 |
| 2015-03-31 | 22.03 | $-2.19 | 0.00 |
| 2014-12-31 | 24.78 | $-2.22 | 0.00 |
| 2014-09-30 | 12.72 | $-1.66 | 0.00 |
| 2014-06-30 | 17.40 | $-1.58 | 0.00 |
| 2014-03-31 | 12.07 | $-1.53 | 0.00 |
| 2013-12-31 | 11.29 | $-1.39 | 0.00 |
| 2013-09-30 | 9.75 | $-1.64 | 0.00 |
| 2013-06-30 | 5.04 | $-1.69 | 0.00 |
| 2013-03-31 | 4.12 | $-1.59 | 0.00 |
| 2012-12-31 | 5.19 | $-1.59 | 0.00 |
| 2012-09-30 | 9.40 | $-1.75 | 0.00 |
| 2012-06-30 | 10.00 | $-1.53 | 0.00 |
| 2012-03-31 | 9.93 | $-1.45 | 0.00 |
| 2011-12-31 | 3.95 | $-1.39 | 0.00 |
| 2011-09-30 | 4.05 | $-1.28 | 0.00 |
| 2011-03-31 | 8.00 | $-1.35 | 0.00 |
| 2010-12-31 | 8.24 | $-1.36 | 0.00 |
| 2010-09-30 | 7.29 | $-1.30 | 0.00 |
| 2010-06-30 | 7.42 | $-1.19 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.217B | $0.000B |
| Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $182.261B | 23.87 |
| Stryker (SYK) | United States | $123.641B | 29.61 |
| Medtronic (MDT) | Ireland | $110.900B | 15.70 |
| Boston Scientific (BSX) | United States | $106.819B | 34.02 |
| EssilorLuxottica (ESLOY) | France | $100.527B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $42.760B | 0.00 |
| Haleon (HLN) | United Kingdom | $37.671B | 27.50 |
| ResMed (RMD) | United States | $32.010B | 30.05 |
| Terumo (TRUMY) | Japan | $25.312B | 35.75 |
| Koninklijke Philips (PHG) | Netherlands | $25.036B | 19.40 |
| Zimmer Biomet Holdings (ZBH) | United States | $24.603B | 15.72 |
| Baxter (BAX) | United States | $18.054B | 12.84 |
| Insulet (PODD) | United States | $11.278B | 50.01 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $10.977B | 0.00 |
| Demant (WILYY) | Denmark | $10.234B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.140B | 26.63 |
| BellRing Brands (BRBR) | United States | $7.808B | 36.57 |
| Lantheus Holdings (LNTH) | United States | $5.398B | 13.45 |
| Haemonetics (HAE) | United States | $4.886B | 24.17 |
| GN Store Nord (GNNDY) | Denmark | $4.400B | 24.71 |
| Perrigo (PRGO) | Ireland | $4.199B | 12.73 |
| Prestige Consumer Healthcare (PBH) | United States | $3.500B | 16.55 |
| Envista Holdings (NVST) | United States | $3.241B | 13.38 |
| QuidelOrtho (QDEL) | United States | $2.820B | 15.65 |
| Neogen (NEOG) | United States | $2.781B | 26.75 |
| Green Thumb Industries (GTBIF) | United States | $2.736B | 54.19 |
| TG Therapeutics (TGTX) | United States | $2.677B | 75.30 |
| Maravai LifeSciences Holdings (MRVI) | United States | $2.647B | 0.00 |
| ICU Medical (ICUI) | United States | $2.641B | 23.31 |
| Agios Pharmaceuticals (AGIO) | United States | $1.904B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $1.711B | 50.14 |
| Verano Holdings (VRNOF) | United States | $1.693B | 0.00 |
| InMode (INMD) | Israel | $1.553B | 8.25 |
| Warby Parker (WRBY) | United States | $1.536B | 0.00 |
| Owens & Minor (OMI) | United States | $1.431B | 12.47 |
| AdaptHealth (AHCO) | United States | $1.263B | 9.41 |
| National Vision Holdings (EYE) | United States | $1.174B | 37.35 |
| AtriCure (ATRC) | United States | $1.069B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.951B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.950B | 0.00 |
| Evolus (EOLS) | United States | $0.790B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.734B | 15.61 |
| Cresco Labs (CRLBF) | United States | $0.695B | 0.00 |
| Quanterix (QTRX) | United States | $0.645B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.634B | 14.91 |
| PetIQ (PETQ) | United States | $0.572B | 18.69 |
| Valneva SE (VALN) | France | $0.530B | 0.00 |
| Jin Medical (ZJYL) | China | $0.515B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.498B | 0.00 |
| Surmodics (SRDX) | United States | $0.463B | 28.97 |
| ZimVie (ZIMV) | United States | $0.459B | 39.12 |
| Biote (BTMD) | United States | $0.448B | 8.59 |
| OraSure Technologies (OSUR) | United States | $0.382B | 12.29 |
| Cerus (CERS) | United States | $0.370B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.364B | 0.00 |
| Zynex (ZYXI) | United States | $0.339B | 46.44 |
| MacroGenics (MGNX) | United States | $0.274B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.274B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.274B | 27.11 |
| Sanara MedTech (SMTI) | United States | $0.252B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.242B | 15.22 |
| Veru (VERU) | United States | $0.195B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.190B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.187B | 0.00 |
| High Tide (HITI) | Canada | $0.178B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.172B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.171B | 0.00 |
| Eagleford Energy (GRUSF) | United States | $0.154B | 74.00 |
| InterCure (INCR) | Israel | $0.141B | 23.77 |
| FitLife Brands (FTLF) | United States | $0.140B | 22.57 |
| Jushi Holdings (JUSHF) | United States | $0.130B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.110B | 0.00 |
| Fonar (FONR) | United States | $0.103B | 8.83 |
| MariMed (MRMD) | United States | $0.099B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.098B | 0.00 |
| Chimerix (CMRX) | United States | $0.094B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.093B | 0.00 |
| Brainsway (BWAY) | Israel | $0.092B | 0.00 |
| Safety Shot (SHOT) | United States | $0.073B | 0.00 |
| Zevia PBC (ZVIA) | United States | $0.067B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.058B | 3.81 |
| Rockwell Medical (RMTI) | United States | $0.050B | 0.00 |
| Apyx Medical (APYX) | United States | $0.050B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.045B | 0.00 |
| United-Guardian (UG) | United States | $0.042B | 15.25 |
| ImmuCell (ICCC) | United States | $0.041B | 0.00 |
| Modular Medical (MODD) | United States | $0.040B | 0.00 |
| Bright Green (BGXX) | United States | $0.040B | 0.00 |
| Exagen (XGN) | United States | $0.028B | 0.00 |
| Nephros (NEPH) | United States | $0.022B | 0.00 |
| Agape ATP (ATPC) | $0.018B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.018B | 0.00 |
| Flora Growth (FLGC) | United States | $0.017B | 0.00 |
| FSD PHARMA (HUGE) | Canada | $0.015B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.014B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.012B | 0.00 |
| GUARDION HEALTH (GHSI) | United States | $0.011B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.009B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
| Leafly Holdings (LFLY) | United States | $0.004B | 0.00 |
| Senestech (SNES) | United States | $0.004B | 0.00 |
| Sharps Technology (STSS) | United States | $0.004B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.002B | 0.00 |
| Lucy Scientific Discovery (LSDI) | Canada | $0.001B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.001B | 0.00 |
| Smart For Life (SMFL) | United States | $0.000B | 0.00 |
| Bruush Oral Care (BRSH) | $0.000B | 0.00 | |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |